Molecular Partners AG Sponsored ADR MOLN 深 滬
交易中 03-26 10:28:59 美东时间
4.21
-0.100
-2.32%
華盛通- 最 高4.29
- 今 開4.29
- 成交量 211股
- 最 低 4.21
- 昨 收 4.3101
- 總市值 1.57亿
- 52周最高 5.36
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.36
- 委 比 -21.65%
- 總股本 3739.92万
- 歷史最高 32.04
- 量 比 1.16
- 振 幅 1.86%
- 歷史最低 3.32
- 每 手 1
- 風險率 0.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
HC Wainwright & Co. Reiterates Buy on Molecular Partners, Maintains $13 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a Buy and maintains $13 price target.
03-16 19:18
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vyome Holdings (NASDAQ:HIND) stock increased by 16.1% to $2.23 during ...
02-02 20:05
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
HC Wainwright & Co. Initiates Coverage On Molecular Partners with Buy Rating, Announces Price Target of $13
HC Wainwright & Co. analyst Robert Burns initiates coverage on Molecular Partners (NASDAQ:MOLN) with a Buy rating and announces Price Target of $13.
01-27 19:16
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Molecular Partners Q3 EPS $(1.65) Misses $(0.46) Estimate
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.46) by 258.7 percent.
2025-10-31 05:49
JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $4
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from $4.5 to $4.
2025-09-03 23:18
